Senior Director, Oncology Clinical Educators at Summit Therapeutics in Field

Job description

About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role: The Senior Director, Oncology Clinical Educators will establish and lead Summit Therapeutics’ field based Clinical Educator function, developing the strategy, infrastructure, and capabilities to support the launch and commercialization of the Company’s oncology portfolio, beginning with its NSCLC bispecific antibody. This leader will oversee the delivery of compliant, on-label education to healthcare professionals to support clinical readiness and appropriate treatment implementation. This leader will lead the national education strategy, establish territory coverage and priorities, and partner cross-functionally while maintaining appropriate compliance oversight. The role is not a sales or marketing role, its educational objectives, performance measures, and incentives will remain independent of sales and marketing performance. Role and Responsibilities: Establish and lead the Oncology Clinical Educator function, defining the vision, strategy, operating model, and annual priorities to support launch readiness and evolving business needs. Develop and execute a national clinical education strategy, including territory design, resource allocation, account prioritization, and educational engagement plans across academic and community oncology settings. Recruit, develop, coach, and retain Clinical Educators, and build a high-performing, clinically credible team, fostering clinical excellence, accountability, collaboration, and continuous professional development. Provide strategic leadership and oversight of field execution, ensuring consistent, high-quality educational engagement and responsiveness to evolving healthcare professional needs. Collaborate with Medical Affairs, Legal, and Compliance to establish and maintain a compliant educational framework, ensuring activities are on-label, use approved materials, address legitimate educational needs, and remain appropriately independent of promotional objectives and incentives. Maintain clear separation between clinical education and promotional a